Nuplazid 34 MG capsule 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FJUT9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,589
Award facts
- Contract value 100% obligated
- $10,588.89 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUPLAZID 34 mg capsules (30-count packages). The delivery order, valued at $10,588.89 with an ultimate completion date of December 18, 2025, carries no set-aside designation, indicating the award was made through open competition. DMS Pharmaceutical Group will perform the work at its Park Ridge facility and will receive funding from the Defense Logistics Agency's Medical Supply Chain division to fulfill this pharmaceutical supply requirement for the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 billion vehicle established to provide comprehensive pharmaceutical and medical supply support to military healthcare facilities worldwide. The PPV-G GEN V represents part of the broader $30.3 billion federal pharmaceutical acquisition strategy and operates on a 30-month base period with three 30-month option periods extending through December 31, 2036. The company's recent substantial contracting activity and established performance across diverse therapeutic categories—including oncology treatments, biologics, vaccines, and specialty pharmaceuticals—demonstrates its capability as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FJUT9?
SPE2DR26FJUT9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 26, 2025.
How much is contract SPE2DR26FJUT9 worth?
The government has obligated $10,589 on SPE2DR26FJUT9.
Is contract SPE2DR26FJUT9 an order under another contract?
Yes. SPE2DR26FJUT9 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUT9 competed?
The extent of competition for SPE2DR26FJUT9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award